Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease

Sumit Sarkar, Balmiki Ray, Jay Sharma, Larry Schmued, Debomoy Lahiri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Alzheimer’s disease (AD) is the most common form of dementia in elderly people and the fifth leading cause of death for people who are 65 years or older (Alz. Assoc. Facts and Figures 2011). Neuropathologically, depositions of amyloid beta (Aβ) plaques in the brain interstitial and phosphorylation of microtubule-associated protein tau (MAPT) within axons are the hallmarks of AD (Hardy and Selkoe 2002). Aβ peptide, which is the proteolytic cleaved product of the transmembrane amyloid precursor protein (APP), is released by enzymatic cleavage by several secretase enzymes. APP is first cleaved by β-secretase (or BACE-1) to produce sAPPβ and a 99 amino acid fragment, which is further cleaved by γ-secretase to produce Aβ peptides (39-44 amino acids residue) (Sambamurti et al. 2002). Alternatively, APP can also be cleaved by another enzyme, α-secretase, to produce sAPPα and a 83 amino acid residue fragment (C83), which is further cleaved by γ-secretase to produce P3 fragment and precludes Aβ production (Lahiri et al. 2003; Marlow et al. 2003). Decreasing the levels of APP and the activities of BACE-1 and γ-secretase has already been identified as potential therapeutic strategies for the treatment of AD (Lahiri et al. 2007a; Imbimbo and Giardina 2011; Vassar and Kandalepas 2011). The schematic diagram in Figure 11.1 shows the major APP processing pathways.

Original languageEnglish (US)
Title of host publicationChemistry and Pharmacology of Naturally Occurring Bioactive Compounds
PublisherCRC Press
Pages259-271
Number of pages13
ISBN (Electronic)9781439891681
ISBN (Print)9781439891674
DOIs
StatePublished - Jan 1 2013

Fingerprint

Amyloid Precursor Protein Secretases
Curcumin
Amyloid beta-Protein Precursor
Alzheimer Disease
Amino Acids
Peptides
Phosphorylation
Microtubule-Associated Proteins
Schematic diagrams
Enzymes
Amyloid
Axons
Dementia
Cause of Death
Brain
Therapeutics
Processing

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemistry(all)

Cite this

Sarkar, S., Ray, B., Sharma, J., Schmued, L., & Lahiri, D. (2013). Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease. In Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds (pp. 259-271). CRC Press. https://doi.org/10.1201/b13867

Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease. / Sarkar, Sumit; Ray, Balmiki; Sharma, Jay; Schmued, Larry; Lahiri, Debomoy.

Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds. CRC Press, 2013. p. 259-271.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sarkar, S, Ray, B, Sharma, J, Schmued, L & Lahiri, D 2013, Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease. in Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds. CRC Press, pp. 259-271. https://doi.org/10.1201/b13867
Sarkar S, Ray B, Sharma J, Schmued L, Lahiri D. Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease. In Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds. CRC Press. 2013. p. 259-271 https://doi.org/10.1201/b13867
Sarkar, Sumit ; Ray, Balmiki ; Sharma, Jay ; Schmued, Larry ; Lahiri, Debomoy. / Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease. Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds. CRC Press, 2013. pp. 259-271
@inbook{369d7ae02a72475ab78fe7b00bb89e6c,
title = "Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease",
abstract = "Alzheimer’s disease (AD) is the most common form of dementia in elderly people and the fifth leading cause of death for people who are 65 years or older (Alz. Assoc. Facts and Figures 2011). Neuropathologically, depositions of amyloid beta (Aβ) plaques in the brain interstitial and phosphorylation of microtubule-associated protein tau (MAPT) within axons are the hallmarks of AD (Hardy and Selkoe 2002). Aβ peptide, which is the proteolytic cleaved product of the transmembrane amyloid precursor protein (APP), is released by enzymatic cleavage by several secretase enzymes. APP is first cleaved by β-secretase (or BACE-1) to produce sAPPβ and a 99 amino acid fragment, which is further cleaved by γ-secretase to produce Aβ peptides (39-44 amino acids residue) (Sambamurti et al. 2002). Alternatively, APP can also be cleaved by another enzyme, α-secretase, to produce sAPPα and a 83 amino acid residue fragment (C83), which is further cleaved by γ-secretase to produce P3 fragment and precludes Aβ production (Lahiri et al. 2003; Marlow et al. 2003). Decreasing the levels of APP and the activities of BACE-1 and γ-secretase has already been identified as potential therapeutic strategies for the treatment of AD (Lahiri et al. 2007a; Imbimbo and Giardina 2011; Vassar and Kandalepas 2011). The schematic diagram in Figure 11.1 shows the major APP processing pathways.",
author = "Sumit Sarkar and Balmiki Ray and Jay Sharma and Larry Schmued and Debomoy Lahiri",
year = "2013",
month = "1",
day = "1",
doi = "10.1201/b13867",
language = "English (US)",
isbn = "9781439891674",
pages = "259--271",
booktitle = "Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds",
publisher = "CRC Press",

}

TY - CHAP

T1 - Role of Curcumin in ameliorating Neuroinflammation and neurodegeneration associated with alzheimer’s disease

AU - Sarkar, Sumit

AU - Ray, Balmiki

AU - Sharma, Jay

AU - Schmued, Larry

AU - Lahiri, Debomoy

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Alzheimer’s disease (AD) is the most common form of dementia in elderly people and the fifth leading cause of death for people who are 65 years or older (Alz. Assoc. Facts and Figures 2011). Neuropathologically, depositions of amyloid beta (Aβ) plaques in the brain interstitial and phosphorylation of microtubule-associated protein tau (MAPT) within axons are the hallmarks of AD (Hardy and Selkoe 2002). Aβ peptide, which is the proteolytic cleaved product of the transmembrane amyloid precursor protein (APP), is released by enzymatic cleavage by several secretase enzymes. APP is first cleaved by β-secretase (or BACE-1) to produce sAPPβ and a 99 amino acid fragment, which is further cleaved by γ-secretase to produce Aβ peptides (39-44 amino acids residue) (Sambamurti et al. 2002). Alternatively, APP can also be cleaved by another enzyme, α-secretase, to produce sAPPα and a 83 amino acid residue fragment (C83), which is further cleaved by γ-secretase to produce P3 fragment and precludes Aβ production (Lahiri et al. 2003; Marlow et al. 2003). Decreasing the levels of APP and the activities of BACE-1 and γ-secretase has already been identified as potential therapeutic strategies for the treatment of AD (Lahiri et al. 2007a; Imbimbo and Giardina 2011; Vassar and Kandalepas 2011). The schematic diagram in Figure 11.1 shows the major APP processing pathways.

AB - Alzheimer’s disease (AD) is the most common form of dementia in elderly people and the fifth leading cause of death for people who are 65 years or older (Alz. Assoc. Facts and Figures 2011). Neuropathologically, depositions of amyloid beta (Aβ) plaques in the brain interstitial and phosphorylation of microtubule-associated protein tau (MAPT) within axons are the hallmarks of AD (Hardy and Selkoe 2002). Aβ peptide, which is the proteolytic cleaved product of the transmembrane amyloid precursor protein (APP), is released by enzymatic cleavage by several secretase enzymes. APP is first cleaved by β-secretase (or BACE-1) to produce sAPPβ and a 99 amino acid fragment, which is further cleaved by γ-secretase to produce Aβ peptides (39-44 amino acids residue) (Sambamurti et al. 2002). Alternatively, APP can also be cleaved by another enzyme, α-secretase, to produce sAPPα and a 83 amino acid residue fragment (C83), which is further cleaved by γ-secretase to produce P3 fragment and precludes Aβ production (Lahiri et al. 2003; Marlow et al. 2003). Decreasing the levels of APP and the activities of BACE-1 and γ-secretase has already been identified as potential therapeutic strategies for the treatment of AD (Lahiri et al. 2007a; Imbimbo and Giardina 2011; Vassar and Kandalepas 2011). The schematic diagram in Figure 11.1 shows the major APP processing pathways.

UR - http://www.scopus.com/inward/record.url?scp=85054400212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054400212&partnerID=8YFLogxK

U2 - 10.1201/b13867

DO - 10.1201/b13867

M3 - Chapter

AN - SCOPUS:85054400212

SN - 9781439891674

SP - 259

EP - 271

BT - Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds

PB - CRC Press

ER -